발작성야간혈색소뇨증 - 시장 인사이트, 역학 및 시장 예측(2036년)

Key Highlights:

• The Paroxysmal Nocturnal Hemoglobinuria market size in the 7MM is expected to grow from USD 1,554 million in 2025.
• The Paroxysmal Nocturnal Hemoglobinuria market is projected to grow significantly by 2036.

Paroxysmal Nocturnal Hemoglobinuria Market and Epidemiology Analysis

• The United States accounted for the highest Paroxysmal Nocturnal Hemoglobinuria Market Size among the 7MM around 85% of the total market size.
• The total diagnosed prevalent cases of PNH in the 7MM were ~ 12,000 in 2025. These cases are expected to increase during the forecast period (2026-2036).
• Paroxysmal Nocturnal Hemoglobinuria is a rare nonmalignant clonal hematological disorder that is characterized by a deficiency of the GPI-linked complement regulators on the membrane of hematopoietic cells, which renders them susceptible to complement-mediated damage.
• Formerly, Paroxysmal Nocturnal Hemoglobinuria Diagnosis relied on Ham and sucrose tests, now replaced by flow cytometry (FCM) detecting GPI-anchored protein anomalies using monoclonal antibodies or FLAER. FLAER is suitable for nucleated cells but not red blood cells due to glycophorin interference. Also, the lack of international guidelines for proper screening and diagnosis leads to treatment delays.
• Historically, Paroxysmal Nocturnal Hemoglobinuria Treatment was exclusively supportive, and the median survival of patients was 15-20 years, thrombosis being the major cause of death. Supportive measures included corticosteroids during hemolytic attacks, androgen therapy, and red blood cell transfusions for the treatment of anemia, as well as anticoagulant therapy to treat/prevent thrombotic events. However, the use of these palliative measures was not evidence-based, their effectiveness was limited, and they were not devoid of adverse events. Allogeneic HSC transplant was and continues to be, indeed, the only curative Paroxysmal Nocturnal Hemoglobinuria Treatment, but it is reserved for young patients with concurrent bone marrow failure because of transplant-related morbidity and mortality.
• Eculizumab, the first developed complement factor inhibitor, Complement C5 Inhibitors, blocking the terminal complement cascade. Given the benefits of the complement inhibition strategy, changing the natural history of this disease, several novel Paroxysmal Nocturnal Hemoglobinuria Drugs against C5 (terminal inhibitors) or factors upstream C5 (proximal inhibitors) have been developed with the aim of further improving the Paroxysmal Nocturnal Hemoglobinuria Treatment.
• The disease-modifying therapeutic strategy for PNH includes complement inhibition therapy, with Paroxysmal Nocturnal Hemoglobinuria Drugs like SOLIRIS, ULTOMIRIS, and EMPAVELI approved by the FDA, and considered the gold standard. However, safety concerns are associated with eculizumab and ravulizumab, including the risk of meningococcal infections and the persistence of extravascular hemolysis in some individuals treated with eculizumab.

Paroxysmal Nocturnal Hemoglobinuria Market size and forecast:

• 2025 Market Size: USD 1,554 million in 2025
• Largest Market: United States

Key Factors Driving the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

Rising prevalence of PNH

The total diagnosed prevalent cases of PNH in the 7MM were ~ 12,000 in 2025. These cases are expected to increase during the forecast period (2026-2036).

Current treatment in the PNH Market

The introduction of complement inhibitors transformed PNH care. SOLIRIS (eculizumab, Alexion/AstraZeneca) was the first therapy, followed by ULTOMIRIS (ravulizumab, AstraZeneca), offering longer dosing intervals. Supportive measures such as transfusions and anticoagulation remain adjuncts.

PNH competitive landscape

Pipeline activity is robust, with oral complement inhibitors like danicopan (AstraZeneca), iptacopan (Novartis), and crovalimab (Roche) leading the way. Other targets include proximal inhibitors (factor B/D blockade) and gene therapy approaches aimed at long-term disease modification.

Paroxysmal Nocturnal Hemoglobinuria Disease Understanding

Paroxysmal Nocturnal Hemoglobinuria is a rare acquired disorder that affects the pluripotent hematopoietic stem cells, which can impact erythrocytes, leukocytes, thrombocytes, and potentially some endothelial cells. This condition arises from a somatic mutation in the X-linked PIG-A gene, which is involved in synthesizing the glycosylphosphatidylinositol (GPI) anchor required for attaching certain proteins to the cell membrane.

The mutation leads to a deficiency in the GPI anchor, resulting in the underexpression of crucial proteins, such as the complement regulatory proteins 'decay-accelerating factor' (DAF or CD55) and 'membrane inhibitor of reactive lysis' (MIRL or CD59), on the surface of the hematopoietic stem cells and the cells derived from them. This deficiency makes red blood cells more susceptible to attack by the complement system, causing complement-mediated intravascular hemolysis. As a consequence, free hemoglobin levels in the plasma increase, which binds to nitric oxide, leading to its depletion.

Paroxysmal Nocturnal Hemoglobinuria Diagnosis

PNH diagnosis was formerly comforted by in vitro complement activation by either acidity (Ham test) or osmolarity (sucrose test). These tests are obsolete as diagnosing PNH by flow cytometry (FCM) refers to detecting a pathognomonic anomaly. GPI-anchored proteins can be detected after labeling the cells with monoclonal antibodies (for example, anti-CD55 or anti-CD59) or a reagent known as fluorescein-tagged proaerolysin (FLAER), which binds to the glycan portion of the GPI anchor. FLAER is best used on nucleated cells; it does not stain red blood cells, as red blood cells express high glycophorin levels, a protein that binds to aerolysin and interferes with the assay.

Paroxysmal Nocturnal Hemoglobinuria Treatment

Treatment with a C5 inhibitor is the standard for patients with PNH. Eculizumab (SOLIRIS, Alexion Pharmaceuticals) and ravulizumab (ULTOMIRIS, Alexion Pharmaceuticals) are humanized monoclonal antibodies that block terminal complement activation at C5 and inhibit the formation of C5a and C5b. Eculizumab was approved by the US FDA in 2007, and ravulizumab in 2018. These agents bind to the same C5 epitope and have the same mechanism of action; ravulizumab was engineered from eculizumab to have a longer half-life. Both drugs are administered via IV infusion. Pegcetacoplan, the first C3 inhibitor for the Paroxysmal Nocturnal Hemoglobinuria Treatment, was also recently approved by the FDA and EMA.

Paroxysmal Nocturnal Hemoglobinuria Epidemiology

The Paroxysmal Nocturnal Hemoglobinuria epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total diagnosed prevalent cases, gender-specific cases, age-specific cases, and total treated cases in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2022 to 2036.

Key Findings from Paroxysmal Nocturnal Hemoglobinuria Epidemiological Analysis and Forecast:

• The total diagnosed prevalent cases of PNH in the 7MM were ~ 12,000 in 2025. These cases are expected to increase during the forecast period (2026-2036).
• Among EU4 and the UK, the highest diagnosed prevalent cases of PNH disease were recorded in UK (~2,500) followed by the Germany (~1,000), in 2025. On the other hand, Italy accounted for the least cases, approximately 200 cases in 2025.
• In 2025 females accounted for ~3,500 cases as compared to ~3,000 cases in males in the United States.
• In Japan the trend of prevalence in gender was observed different as male were more affected by PNH rather than female which was analyzed in other remaining countries.

Paroxysmal Nocturnal Hemoglobinuria Epidemiology Segmentation:

• Total diagnosed prevalent cases
• Gender-specific cases
• Age-specific cases
• Total treated cases

Paroxysmal Nocturnal Hemoglobinuria Drugs Market Chapters

The section dedicated to drugs in the Paroxysmal Nocturnal Hemoglobinuria therapeutics market report provides an in-depth evaluation of late-stage Paroxysmal Nocturnal Hemoglobinuria pipeline drugs (Phase III and Phase II). The drug chapters section provides valuable information on various aspects related to Paroxysmal Nocturnal Hemoglobinuria Clinical Trials, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting Paroxysmal Nocturnal Hemoglobinuria.

Paroxysmal Nocturnal Hemoglobinuria Marketed Therapies

• ULTOMIRIS (ravulizumab): AstraZeneca (Alexion Pharmaceuticals)

ULTOMIRIS is a complement inhibitor for treating adult patients with PNH. It is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in several therapeutic areas, including hematology, nephrology, and neurology.

In December 2018, the US FDA approved ULTOMIRIS (ravulizumab) for treating PNH. Following this, the European Union authorized it in July 2019, and Japan's MHLW approved it in June 2019 for PNH treatment. In June 2021, the US FDA expanded its approval to include children and adolescents (one month and older) with PNH.

• EMPAVELI/ ASPAVELI (pegcetacoplan): Apellis Pharmaceuticals/ Swedish Orphan Biovitrum

Pegcetacoplan (APL-2) is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, leading to the onset and progression of many serious diseases. Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. EMPAVELI is a complement inhibitor indicated to treat adult patients with PNH.

In April 2021, the FDA approved EMPAVELI (pegcetacoplan) injection to treat adults with PNH. EMPAVELI was the first PNH treatment that was bound to complement protein C3.

Paroxysmal Nocturnal Hemoglobinuria Emerging Therapies

• Pozelimab (REGN3918): Regeneron Pharmaceuticals

Pozelimab is an investigational, fully-human monoclonal antibody designed to block complement factor C5 and prevent the destruction of red blood cells (hemolysis) that cause the symptoms of PNH and other diseases mediated by complement pathway activity. It is an IgG4 antibody that binds with high affinity to wild-type and variant human C5 and blocks its activity. Pozelimab was invented using Regeneron's proprietary VelocImmune technology, which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies.

Regeneron Pharmaceuticals reported that results from the Phase III study evaluating Pozelimab (C5 antibody) in combination with cemdisiran (C5 siRNA therapy) in PNH are expected in Q4 2026 or Q1 2027.

• OMS-906 (zaltenibart)

Zaltenibart (OMS906), a lead monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the alternative pathway, is advancing through a Phase II program for paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 glomerulopathy (C3G). In a single-ascending-dose Phase I study in healthy subjects, the drug was well tolerated, with no safety signals of concern. OMS906 has received ODD from the FDA for the treatment of PNH.

• Ruxoprubart (NM8074): NovelMed

Ruxoprubart, a lead humanized monoclonal antibody, selectively binds to protein Bb of the alternative pathway, distinguishing itself from Iptacopan (FABHALTA) by exhibiting no affinity for Factor B. As a potent blocker of the Alternative Pathway, Ruxoprubart has demonstrated promising results, having successfully completed its Phase I trial in healthy volunteers.

Paroxysmal Nocturnal Hemoglobinuria Market Outlook

Substantial progress in the biology and Paroxysmal Nocturnal Hemoglobinuria treatment has occurred over the past two decades, making PNH a model for progress in precision medicine. A thorough understanding of the molecular and cellular underpinnings of PNH has led to the development of a targeted therapy, which has altered the natural history of the disease. However, there is still room for improvement in caring for Paroxysmal Nocturnal Hemoglobinuria Patients. The future approvals of Paroxysmal Nocturnal Hemoglobinuria move toward personalized patient-centered care with better options to reduce the frequency and self-administer medication. Auto-injections of SC compounds and oral drugs will increase patient autonomy, and compliance will become critical.

The US has the highest Paroxysmal Nocturnal Hemoglobinuria Drugs Market Share, followed by the EU4 and the UK, and Japan. Rising awareness about the disease and supporting government policies, funds, approvals, and emerging research would drive the market significantly in forecast periods (2026-2036).

Paroxysmal Nocturnal Hemoglobinuria Market Insights

• The leading Paroxysmal Nocturnal Hemoglobinuria Companies such as Alexion Pharmaceuticals, Novartis, Chugai Pharmaceuticals, Apellis Pharmaceuticals, and Others. The details of the country-wise and therapy-wise market size have been provided below.
• In the Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size in the 7MM, the United States accounted for the highest market share, i.e., ~85% in 2024, followed by the United Kingdom.
• Among EU4 and the UK, the United Kingdom accounted for the highest Paroxysmal Nocturnal Hemoglobinuria Market Size in 2024.
• The United States accounted for more than USD 1,000 million in 2024.
• Among the emerging therapies, Pozelimab appears to be the drug that can potentially transform the Paroxysmal Nocturnal Hemoglobinuria Drugs Market.

Latest KOL Views

To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of Paroxysmal Nocturnal Hemoglobinuria, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions such as the University of Tsukuba, Duke University, University of Glasgow, Washington University School of Medicine, etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Paroxysmal Nocturnal Hemoglobinuria market, which will assist our clients in analyzing the overall epidemiology and market scenario.

Paroxysmal Nocturnal Hemoglobinuria Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving Paroxysmal Nocturnal Hemoglobinuria Treatment Market Landscape.

Conjoint Analysis analyzes multiple approved and Paroxysmal Nocturnal Hemoglobinuria emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for Paroxysmal Nocturnal Hemoglobinuria, one of the most important primary endpoints was achieving LDH percentage change, transfusion avoidance, etc. Based on these, the overall efficacy is evaluated.

Further, the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Paroxysmal Nocturnal Hemoglobinuria Market Access and Reimbursement

Because newly authorized Paroxysmal Nocturnal Hemoglobinuria drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Paroxysmal Nocturnal Hemoglobinuria Market Report Scope

• The Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current Paroxysmal Nocturnal Hemoglobinuria Treatment Market Landscape and result in an overall market shift has been provided in the report.
• The Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report also encompasses a comprehensive analysis of the market, providing an in-depth examination of its historical and projected market size (2022-2036). It also includes the Paroxysmal Nocturnal Hemoglobinuria Drugs Market Share of therapies, detailed assumptions, and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
• The Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report includes qualitative insights that provide an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM Paroxysmal Nocturnal Hemoglobinuria Drugs Market.

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Report Insights

• Patient-based Paroxysmal Nocturnal Hemoglobinuria Market Forecasting
• Therapeutic Approaches
• Paroxysmal Nocturnal Hemoglobinuria Market Size and Trends
• Existing Paroxysmal Nocturnal Hemoglobinuria Drugs Market Opportunity

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Report Key Strengths

• 11-year Paroxysmal Nocturnal Hemoglobinuria Market Forecast
• The 7MM Coverage
• Paroxysmal Nocturnal Hemoglobinuria Epidemiology Segmentation
• Key Cross Competition

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Report Assessment

• Current Paroxysmal Nocturnal Hemoglobinuria Treatment Practices
• Reimbursements
• Paroxysmal Nocturnal Hemoglobinuria Drugs Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis, Unmet Needs)

Key Questions answered through our Paroxysmal Nocturnal Hemoglobinuria Market Report:

• Would there be any changes observed in the current treatment approach?
• Will there be any improvements in Paroxysmal Nocturnal Hemoglobinuria management recommendations?
• Would research and development advances pave the way for future tests and therapies for Paroxysmal Nocturnal Hemoglobinuria?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Paroxysmal Nocturnal Hemoglobinuria?
• What kind of uptake will the new therapies witness in the coming years in Paroxysmal Nocturnal Hemoglobinuria patients?

Table of Contents

1 Key Insights

2 Report Introduction

3 PNH Market Overview at a Glance

• 3.1 Market Share (%) Distribution of PNH by Country in 2025 in the 7MM
• 3.2 Market Share (%) Distribution of PNH by Country in 2036 in the 7MM

4 Epidemiology and Market Forecast Methodology

5 Executive Summary of PNH

6 Key Events

7 Disease Background and Overview

• 7.1 Introduction
• 7.2 Signs and Symptoms
• 7.3 Causes
• 7.4 Clinical Forms of PNH
• 7.5 Clinical Manifestations
• 7.6 Prognosis of PNH
• 7.7 Pathophysiology of PNH
• 7.8 Diagnosis
  • 7.8.1 Summary and Diagnostic Criteria
  • 7.8.2 Differential Diagnosis

8 Treatment and Management

• 8.1 The Current Standard of Care
• 8.2 Supportive and Immunosuppressive Treatments
• 8.3 Treatment Guidelines
  • 8.3.1 Reference Guide for the Management of Paroxysmal Nocturnal Hemoglobinuria (Reiwa 4th Edition)
• 8.4 Treatment Algorithm

9 Epidemiology and Patient Population

• 9.1 Key Findings
• 9.2 Assumptions and Rationale
• 9.3 Total Diagnosed Prevalent Cases of PNH in 7MM
• 9.4 Total Treated Cases of PNH in 7MM
• 9.5 The United States
  • 9.5.1 Total Diagnosed Prevalent Cases of PNH in the United States
  • 9.5.2 Gender-specific Cases of PNH in the United States
  • 9.5.3 Age group-specific Cases of PNH in the United States
  • 9.5.4 Treated Cases of PNH in the United States
• 9.6 EU4 and the UK
  • 9.6.1 Total Diagnosed Prevalent Cases of PNH in EU4 and the UK
  • 9.6.2 Gender-specific Cases of PNH in EU4 and the UK
  • 9.6.3 Age-specific Cases of PNH in EU4 and the UK
  • 9.6.4 Total Treated Cases of PNH in EU4 and the UK
• 9.7 Japan
  • 9.7.1 Total Diagnosed Prevalent Cases of PNH Japan
  • 9.7.2 Gender-specific Cases of PNH in Japan
  • 9.7.3 Age group-specific Cases of PNH in Japan
  • 9.7.4 Treated Cases of PNH in Japan

10 Patient Journey

11 Marketed Therapies

• 11.1 Key cross
• 11.2 ULTOMIRIS (ravulizumab): AstraZeneca (Alexion Pharmaceuticals)
  • 11.2.1 Product Description
  • 11.2.2 Regulatory Milestone
  • 11.2.3 Other Developmental Activities
  • 11.2.4 Clinical Developmental Activities
  • 11.2.5 Safety and efficacy
• 11.3 EMPAVELI/ ASPAVELI (pegcetacoplan): Apellis Pharmaceuticals/ Swedish Orphan Biovitrum
  • 11.3.1 Product Description
  • 11.3.2 Regulatory Milestone
  • 11.3.3 Other Developmental Activities
  • 11.3.4 Clinical Developmental Activities
  • 11.3.5 Safety and Efficacy
• 11.4 VOYDEYA (danicopan): AstraZeneca (Alexion Pharmaceuticals)
  • 11.4.1 Product Description
  • 11.4.2 Regulatory Milestone
  • 11.4.3 Other Developmental Activity
  • 11.4.4 Clinical Development
  • 11.4.5 Safety and efficacy
• 11.5 FABHALTA (iptacopan): Novartis
  • 11.5.1 Product Description
  • 11.5.2 Regulatory Milestone
  • 11.5.3 Other Developmental Activities
  • 11.5.4 Clinical Development
  • 11.5.5 Safety and Efficacy
• 11.6 PIASKY (Crovalimab): Hoffmann-La Roche/Chugai Pharmaceutical
  • 11.6.1 Product Description
  • 11.6.2 Regulatory Milestone
  • 11.6.3 Other Developmental Activities
  • 11.6.4 Clinical Development
  • 11.6.5 Safety and Efficacy

12 Emerging Therapies

• 12.1 Key Cross Competition
• 12.2 Pozelimab (REGN3918) + Cemdisiran: Regeneron Pharmaceuticals/Alnylam Pharmaceuticals
  • 12.2.1 Product Description
  • 12.2.2 Other Developmental Activities
  • 12.2.3 Clinical Development
  • 12.2.4 Safety and Efficacy
  • 12.2.5 Analyst View
• 12.3 Zaltenibart (OMS906): Omeros Corporation
  • 12.3.1 Product Description
  • 12.3.2 Other Developmental Activities
  • 12.3.3 Clinical Development
  • 12.3.4 Safety and Efficacy
  • 12.3.5 Analyst View
• 12.4 Ruxoprubart (NM8074): NovelMed Therapeutics
  • 12.4.1 Product Description
  • 12.4.2 Other Developmental Activities
  • 12.4.3 Clinical Development
  • 12.4.4 Safety and Efficacy
  • 12.4.5 Analyst View

13 PNH: 7 Major Market Analysis

• 13.1 Key Findings
• 13.2 Conjoint Analysis
• 13.3 Market Outlook
• 13.4 Key Market Forecast Assumptions
• 13.5 Total Market Size of PNH in the 7MM
• 13.6 Total Market Size of PNH by Therapies in the 7MM
• 13.7 United States Market Size
  • 13.7.1 Total Market Size of PNH in the US (2020-2034)
  • 13.7.2 Market Size of PNH by Therapies in the United States (2022-2036)
• 13.8 EU4 and the UK Market Size
  • 13.8.1 Total Market Size of PNH in EU4 and the UK (2022-2036)
  • 13.8.2 Market Size of PNH by Therapies in EU4 and the UK (2022-2036)
• 13.9 Japan Market Size
  • 13.9.1 Total Market Size of PNH in Japan (2022-2036)
  • 13.9.2 Market Size of PNH by Therapies (2020-2034)

14 KOL Views

15 SWOT Analysis

16 Unmet Needs

17 Reimbursement Scenario in PNH

• 17.1 Patient Access Programs
  • 17.1.1 The United States
• 17.2 HTA Decisions
  • 17.2.1 Germany
  • 17.2.2 France
  • 17.2.3 Italy
  • 17.2.4 Spain
  • 17.2.5 The United Kingdom
• 17.3 Japan

18 Appendix

• 18.1 Bibliography
• 18.2 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer